Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model

被引：0
|
作者：
Ochoa-Callejero, Laura [1 ]
Perez-Martinez, Laura [1 ]
Rubio-Mediavilla, Susana [2 ]
Oteo, Jose A. [1 ]
Martinez, Alfredo [1 ]
Blanco, Jose R. [1 ]
机构：
[1] Ctr Biomed Res La Rioja CIBIR, Logrono, Spain
[2] Hosp San Pedro, Logrono, Spain
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-LB-173
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-173
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Maraviroc -: Anti-HIV agent viral entry inhibitor chemokine CCR5 antagonist
    Ginesta, JB
    Castañer, J
    Bozzo, J
    Bayés, M
    [J]. DRUGS OF THE FUTURE, 2005, 30 (05) : 469 - 477
  • [32] Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
    Joaquin Merino, Jose
    Muneton-Gomez, Vilma
    Muneton-Gomez, Cesar
    Angeles Perez-Izquierdo, Maria
    Loscertales, Maria
    Toledano Gasca, Adolfo
    [J]. BIOMOLECULES, 2020, 10 (02)
  • [33] NINTEDANIB PREVENTS THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN A MOUSE MODEL OF FIBROSIS
    Tovar, V.
    Moeni, A.
    Torrecilla, S.
    Higuera, M.
    Peix, J.
    Quetglas, I. M.
    Rodriguez-Carunchio, L.
    Sole, M.
    Llovet, J. M.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S391 - S391
  • [34] Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker
    Arribas Lopez, Jose R.
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2008, 26 : 23 - 27
  • [35] Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc
    Lemoine, Remy C.
    Petersen, Ann C.
    Setti, Lina
    Baldinger, Thomas
    Wanner, Jutta
    Jekle, Andreas
    Heilek, Gabrielle
    deRosier, Andre
    Ji, Changhua
    Rotstein, David M.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (05) : 1674 - 1676
  • [36] The CCR5 Antagonist Maraviroc Reduces the Potential for Gastric Cancer Dissemination in Rodent Models of Peritoneal Metastasis
    Renga, Barbara
    D'Amore, Claudio
    Graziosi, Luigina
    Mencarelli, Andrea
    Bruno, Angela
    Francisci, Daniela
    Baldelli, Franco
    Distrutti, Eleonora
    Donini, Annibale
    Fiorucci, Stefano
    Cavazzoni, Emanuel
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S524 - S524
  • [37] INHIBITION OF HCV REPLICATION BY CCR5 BLOCKADE WITH CENICRIVIROC AND MARAVIROC
    Sherman, K. E.
    Kong, L.
    Blackard, J. T.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S684 - S684
  • [38] Investigating HIV-1 Resistance to CCR5 Antagonist Maraviroc for the Design of New Prevention Strategies
    Flynn, Jacqueline K.
    Roche, Michael
    Paukovics, Geza
    Salimi, Hamid
    Duncan, Renee C.
    Moore, Miranda S.
    Ellet, Anne
    Gray, Lachlan R.
    Jubb, Becky
    Westby, Mike
    Purcell, Damian F. J.
    Lewin, Sharon R.
    Lee, Benhur
    Payne, Richard J.
    Churchill, Melissa J.
    Gorry, Paul R.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A212 - A212
  • [39] The CC Chemokine Receptor 5 (CCR5) antagonist Maraviroc inhibits drug-choice in Sprague Dawley rats
    Mason, Briana
    Seaman, Robert, Jr.
    Collins, Gregory
    [J]. FASEB JOURNAL, 2021, 35
  • [40] A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
    Neff, C. Preston
    Kurisu, Theresa
    Ndolo, Thomas
    Fox, Kami
    Akkina, Ramesh
    [J]. PLOS ONE, 2011, 6 (06):
12345